 |
|
|
| |
The Effects of Combining Two Gilead Direct Acting Antivirals GS-9256+GS-9190, Ribavirin, and Pegylated Interferon on the Detection of Drug Resistance Mutations Early in Treatment of HCV
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
CM Hebner, R Martin, S Knox, MD Miller, H Mo, ES Svarovskaia
Gilead Sciences, Foster City, CA United States
|
| |
|
|
|
|
|
